Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM and Martin-Duque P (2021). Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy. Acta Biomaterialia  vol. 134, 593-604.  

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J and Halldén G (2019). Systemic delivery and SPECT/CT in vivo imaging of ¹²⁵I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports  vol. 9, (1)  

Hallden G, Wang Y, Wong H-H and Lemoine NR (2019). ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY. Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology  

Nattress CB and Halldén G (2018). Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Letters  vol. 434, 56-69.  

Baker AT, Aguirre-Hernández C, Halldén G and Parker AL (2018). Designer oncolytic adenovirus: Coming of age. Cancers  vol. 10, (6)  

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL and Halldén G (2018). The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics  vol. 17, (2) 575-587.  

Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu YJ and Halldén G (2018). Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagy. Oncogenesis  vol. 7, (1)  

Hallden G (2017). Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses. HUMAN GENE THERAPY  vol. 28, (8) A6-A6.  

Aguirre-Hernandez C, Millan JS and Hallden G (2016). The adenoviral Ad Delta Delta mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells. 

Pantelidou C, Cherubini G, Lemoine NR and Halldén G (2016). The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. Oncotarget  vol. 7, (13) 15703-15724.  

Sweeney K and Halldén G (2016). Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother  vol. 5, 45-57.  

Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H and Hallden G (2016). Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  vol. 38, S58-S58.  

Hallden G, Wang Y, Wong H-H and Lemoine NR (2014). 18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY. Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology  

Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G, Gillespie D and Portella G (2013). Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells. Endocr Relat Cancer  vol. 20, (5) 633-647.  

Halldén G and Portella G (2012). Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets  vol. 16, (10) 945-958.  

Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR and Halldén G (2012). Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models. Hum Gene Ther  vol. 23, (9) 1003-1015.  

Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F, Formisano P and Portella G (2012). Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. Hum Gene Ther  vol. 23, (6) 623-634.  

Sweeney KG, Cheong SC, Lemoine NR and Hallden G (2012). Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells. 

Maya-Pineda HR, Miranda-Rota E, Lemoine NR and Halldén G (2012). Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells. 

Halldén G (2012). Adenoviral gene expression and replication in human tumor explant models. Methods Mol Biol  vol. 797, 65-78.  

Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR and Halldén G (2012). Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One  vol. 7, (10)  

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR and Halldén G (2011). The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther  vol. 18, (12) 1157-1165.  

Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR and Halldén G (2011). An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther  vol. 18, (10) 734-743.  

Pantelidou C, Cherubini G, Lemoine NR and Hallden G (2011). Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene. HUMAN GENE THERAPY  vol. 22, (10) A119-A120.  

Sweeney K, Cheong SC, Lemoine N and Hallden G (2011). A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells. HUMAN GENE THERAPY  vol. 22, (10) A122-A122.  

Maya-Pineda H, Miranda E, Lemoine N and Hallden G (2011). Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells. HUMAN GENE THERAPY  vol. 22, (10) A104-A104.  

Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G and McNeish IA (2010). Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene  vol. 29, (45) 6051-6063.  

Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR and Halldén G (2010). Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther  vol. 21, (10) 1311-1325.  

Ekblad M and Halldén G (2010). Adenovirus-based therapy for prostate cancer. Curr Opin Mol Ther  vol. 12, (4) 421-431.  

Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR and Halldén G (2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res  vol. 16, (2) 541-553.  

Lee M, Choi S, Halldén G, Yo SJ, Schichnes D and Aponte GW (2009). P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am J Physiol Gastrointest Liver Physiol  vol. 297, (4) G641-G654.  

Hallden G (2009). Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON  vol. 14, S61-S67.  

Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR and Halldén G (2009). Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res  vol. 15, (5) 1730-1740.  

Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G and Portella G (2008). Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947. CLIN CANCER RES  vol. 14, (20) 6505-6514.  

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y and Seymour LW (2008). Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther  vol. 19, (9) 873-886.  

Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V, Shen J and Fisher K (2008). Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus. Hum Gene Ther   

Cheong SC, Wang Y, Meng J-H, Hill R, Sweeney K, Kirn D, Lemoine NR and Halldén G (2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther  vol. 15, (1) 40-50.  

Gaballah K, Hills A, Curiel D, Hallden G, Harrison P and Partridge M (2007). Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses. CANCER RES  vol. 67, (15) 7284-7294.  

Choi S, Lee M, Shiu AL, Yo SJ, Hallden G and Aponte GW (2007). GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. AM J PHYSIOL-GASTR L  vol. 292, (5) G1366-G1375.  

Bapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G and Lemoine N (2006). Oncolytic virotherapy for nasopharyngeal cancer. Clinical Otolaryngology  vol. 31, (6) 582-583.  

Liu T-C, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR and Kirn D (2005). Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther  vol. 12, (17) 1333-1346.  

Wang Y, Xue S-A, Hallden G, Francis J, Yuan M, Griffin BE and Lemoine NR (2005). Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res  vol. 65, (4) 1523-1531.  

Lee M, Hadi M, Halldén G and Aponte GW (2005). Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity. J Biol Chem  vol. 280, (1) 125-136.  

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D and Halldén G (2005). A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res  vol. 11, (1) 351-360.  

Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR and Patrick G (2004). Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol  vol. 25, (1) 173-178.  

Liu T-C, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N and Kirn D (2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther  vol. 9, (6) 786-803.  

Halldén G, Thorne SH, Yang J and Kirn DH (2004). Replication-selective oncolytic adenoviruses. Methods Mol Med  vol. 90, 71-90.  

Wang Y, Hallden G, Hill R, Anand A, Liu T-C, Francis J, Brooks G, Lemoine N and Kirn D (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol  vol. 21, (11) 1328-1335.  

Halldén G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, Francis J, Hawkins L and Kirn D (2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther  vol. 8, (3) 412-424.  

Kirn D, Niculescu-Duvaz I, Hallden G and Springer CJ (2002). The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med  vol. 8, (4 Suppl) S68-S73.  

Hallden G, Holehouse EL, Dong X and Aponte GW (1994). Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells. American Journal of Physiology - Gastrointestinal and Liver Physiology  vol. 267, (4 30-4)  

Mulvihill SJ, Hallden G and Debas HT (1989). Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells. Journal of Surgical Research  vol. 46, (4) 327-329.  

Szecowka J, Hallden G, Goldfine ID and Williams JA (1989). Purification of the pancreatic cholecystokinin receptor. Regulatory Peptides  vol. 24, (3) 215-224.